Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change disclosed is a transaction involving a connected person of a PDMR:
- Transaction Date: September 6, 2011
- PDMR: Dr. P. Vallance
- Connected Person: Ms. S. Dexter
- Activity: Purchase of 5,000 Ordinary shares
- Price: 1,284.92 pence per share
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share purchase in accordance with Disclosure Rule 3.1.4R(1)(c).
Investor Verification Checklist
- Verify the total shareholding of Ms. S. Dexter post-transaction.
- Confirm the aggregate number of shares held by Dr. P. Vallance and connected persons.
- Review the company's broader insider trading policy and recent transaction history for patterns.